M31.19 classifies thrombotic microangiopathies that don't fall under hematopoietic stem cell transplantation-associated TMA (M31.11) or the unspecified category (M31.10) — most notably serving as the designated code for thrombotic thrombocytopenic purpura (TTP).
Verified May 8, 2026 · 6 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 0
- Region
- General
Documentation tips
What should appear in the chart to support M31.19.
Source · Editorial brief grounded in 6 cited references ↓
- Provider must name the specific TMA variant — 'TTP' or 'thrombotic thrombocytopenic purpura' in the note locks in M31.19 and prevents a drop to the unspecified M31.10.
- If the TMA is transplant-related, the note must explicitly state the HSCT connection — that routes to M31.11, not M31.19.
- Document any organ manifestations (renal, neurological) as separate diagnoses; they are not integral to M31.19 and should be coded additionally.
- Record relevant lab findings supporting TMA — microangiopathic hemolytic anemia, thrombocytopenia, ADAMTS13 activity level — to substantiate medical necessity for associated procedures and treatments.
- Avoid vague terms like 'thrombotic disorder' or 'microangiopathy NOS' in the impression; these force the coder to M31.10 (unspecified) and may trigger payer scrutiny.
Common coding pitfalls
The recurring mistakes coders make with M31.19 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning the non-billable parent code M31.1 instead of drilling down to M31.10, M31.11, or M31.19 — M31.1 is a header code and will be rejected on claims.
- Using M31.10 (unspecified) when the provider has explicitly documented TTP — M31.19 is the correct and more specific code in that scenario.
- Routing TTP to a hematology chapter code when the provider uses a general purpura term; the ICD-10-CM Tabular List cross-references thrombotic thrombocytopenic purpura directly to M31.19, not to a D-chapter code.
- Failing to add manifestation codes for secondary organ involvement (e.g., acute kidney injury) when documented — M31.19 alone does not capture those complications.
- Confusing M31.19 with purpura codes in the D89 range (e.g., benign hypergammaglobulinemic purpura D89.0, cryoglobulinemic purpura D89.1) — these are explicitly excluded from the M31 category.
Clinical context
Source · Editorial summary grounded in 6 cited references ↓
M31.19 sits under M31.1 (Thrombotic microangiopathy) in the Other necrotizing vasculopathies category (M31), which is part of the Systemic connective tissue disorders section (M30–M36). The code was introduced in FY2022 when M31.1 was expanded into three child codes, allowing coders to distinguish unspecified TMA (M31.10), HSCT-associated TMA (M31.11), and all remaining TMA variants (M31.19). Thrombotic thrombocytopenic purpura is explicitly listed as an 'Applicable To' inclusion under M31.19 in the ICD-10-CM Tabular List, making this the correct billable code when a provider documents TTP.
Use M31.19 when the physician documents TTP or another TMA diagnosis that is neither unspecified nor tied to a hematopoietic stem cell transplant. Do not use the parent code M31.1 — it is no longer billable now that specific child codes exist. If the provider documents TMA without any further specification (no etiology, no transplant context, no TTP), use M31.10. If the TMA is explicitly linked to an HSCT, use M31.11.
This code sits in Chapter 13 (Diseases of the musculoskeletal system and connective tissue) despite being a vascular/hematologic condition by clinical nature. That classification is intentional under ICD-10-CM's systemic connective tissue disorders grouping. No 7th-character extension is required. Code additional manifestations separately per ICD-10-CM syndrome coding guidance when they are not considered integral to the TMA/TTP diagnosis.
Inclusion & exclusion notes
Per the official ICD-10-CM Tabular List.
Source · CDC ICD-10-CM Official Tabular List · 2026
Includes
- Thrombotic thrombocytopenic purpura
Sibling codes
Other billable codes under M31.1 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 6 cited references ↓
01Is TTP always coded to M31.19?
02When does TMA route to M31.11 instead of M31.19?
03Can I still bill M31.1 as the primary diagnosis?
04Should I code organ manifestations separately when billing M31.19?
05Is M31.19 classified as a chronic condition?
06What replaced M31.1 when M31.19 was introduced?
07Are there any Excludes1 or Excludes2 conditions I need to watch for?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M31-/M31.19
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M31.19
- 04icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M31-
- 05icdlist.comhttps://icdlist.com/icd-10/M31.19
- 06vsac.nlm.nih.govhttps://vsac.nlm.nih.gov/context/cs/codesystem/ICD10CM/version/2023/code/M31.19/info
Mira AI Scribe
Mira captures the provider's explicit diagnosis of thrombotic thrombocytopenic purpura or other non-HSCT thrombotic microangiopathy, along with supporting lab findings (ADAMTS13 level, platelet count, LDH, schistocytes on smear) and any documented organ involvement. That specificity prevents a downcode to M31.10 (unspecified TMA) and avoids audit flags from payers who expect clinical documentation to support the M31.19 classification.
See how Mira captures M31.19 documentation